Please login to the form below

Not currently logged in
Email:
Password:

loxapine

This page shows the latest loxapine news and features for those working in and with pharma, biotech and healthcare.

Teva launches first inhaled antipsychotic in US

Teva launches first inhaled antipsychotic in US

Adasuve (loxapine) was originally developed by US company Alexza Pharmaceuticals and becomes the first and only inhaled antipsychotic drug for this indication in the US market. ... According to Teva, the delivery of loxapine using Alexza's proprietary

Latest news

  • EU approves Alexza’s antipsychotic Adasuve EU approves Alexza’s antipsychotic Adasuve

    Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

  • FDA panel backs Alexza’s inhaled antipsychotic drug

    Shares in Alexza climbed more than 70 per cent after the 9-8 vote by the Psychopharmacologic Drugs Advisory Committee (PDAC) improved the chances that Adasuve (loxapine delivered using Alexza's ... The speed of onset of treatment with inhaled loxapine is

  • Schizophrenia treatments

    The product uses the Alexza's Staccato hand-held, disposable inhaler technology which vaporises loxapine by heating a thin film of the agent. . ... Worldwide revenue projections for inhaled loxapine, cariprazine and TC 5619 are represented in figure

  • Alexza schizophrenia drug delayed

    Alexza said it had completed an end-of-review meeting with the FDA for Adusuve Staccato (loxapine) inhalation aerosol, which is being developed for the rapid treatment of agitation in schizophrenia

  • Alexza psychiatric drug delayed

    Alexza Pharmaceuticals has received a Complete Response Letter (CRL)  from the US Food and Drug Administration (FDA) voicing concerns about the safety of Adusuve Staccato (loxapine) inhalation aerosol.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics